JNJ

225.06

-0.27%↓

UNH

365.6

-1.28%↓

TMO

465.98

+0.4%↑

ISRG

446.9

-0.86%↓

ABT

86.58

+0.01%↑

JNJ

225.06

-0.27%↓

UNH

365.6

-1.28%↓

TMO

465.98

+0.4%↑

ISRG

446.9

-0.86%↓

ABT

86.58

+0.01%↑

JNJ

225.06

-0.27%↓

UNH

365.6

-1.28%↓

TMO

465.98

+0.4%↑

ISRG

446.9

-0.86%↓

ABT

86.58

+0.01%↑

JNJ

225.06

-0.27%↓

UNH

365.6

-1.28%↓

TMO

465.98

+0.4%↑

ISRG

446.9

-0.86%↓

ABT

86.58

+0.01%↑

JNJ

225.06

-0.27%↓

UNH

365.6

-1.28%↓

TMO

465.98

+0.4%↑

ISRG

446.9

-0.86%↓

ABT

86.58

+0.01%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

8.79 -1.01

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.73

Máximo

8.85

Métricas clave
By Trading Economics
Ingresos	-6.9M -81M
Ventas	-3.4M 17M
Margen de beneficios	-467.23
Empleados	260
EBITDA	-12M -86M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+204.11% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	66M 821M
Apertura anterior	9.8
Cierre anterior	8.79

Noticias sobre sentimiento de mercado

By Acuity

50%

180 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2026, 23:43 UTC

Noticias de Eventos Importantes

New Zealand's Unemployment Rate Falls in 1Q

5 may 2026, 23:20 UTC

Acciones populares

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 may 2026, 21:48 UTC

Ganancias

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 may 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 may 2026, 00:00 UTC

Charlas de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 may 2026, 22:26 UTC

Charlas de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 may 2026, 22:20 UTC

Charlas de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 may 2026, 22:08 UTC

Ganancias

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 may 2026, 22:07 UTC

Ganancias

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Rev $1.2B >PAAS

5 may 2026, 21:42 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:38 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:30 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:29 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:26 UTC

Ganancias

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q EPS 39c >ALC.EB

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 may 2026, 21:24 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:18 UTC

Ganancias

Mistras Backs 2026 Rev $730M-$750M >MG

5 may 2026, 21:17 UTC

Ganancias

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 may 2026, 21:15 UTC

Ganancias

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 may 2026, 21:12 UTC

Ganancias

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 may 2026, 21:11 UTC

Ganancias

SSR Mining 1Q Rev $581.8M >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q EPS $1.16 >SSRM

5 may 2026, 21:08 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:01 UTC

Ganancias

Intact Financial 1Q EPS C$4.12 >IFC.T

5 may 2026, 21:01 UTC

Acciones populares

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

204.11% repunte

Estimación a 12 Meses

Media 28.13 USD 204.11%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

180 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.